Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Open-market sale Chief Executive Officer sold 3,091 shares at $0.76 ($2,348)
  2. 4 Open-market sale General Counsel sold 2,323 shares at $0.73 ($1,707)
  3. 4 Open-market sale Chief Executive Officer sold 10,847 shares at $0.73 ($7,970)
  4. 4 Open-market sale Sinha Vikas sold 5,251 shares at $0.73 ($3,858)
  5. 4 Open-market sale Chief Accounting Officer sold 1,692 shares at $0.73 ($1,243)
  6. 4 Open-market sale Chief Accounting Officer sold 960 shares at an average $0.74 ($715)
  7. 4 Open-market sale Chief Executive Officer sold 9,731 shares at $0.75 ($7,299)
  8. 4 Open-market sale Sinha Vikas sold 3,400 shares at an average $0.74 ($2,530)
  9. 4 Open-market sale General Counsel sold 1,391 shares at an average $0.74 ($1,035)
  10. 4 Open-market sale General Counsel sold 379 shares at $0.72 ($273)
  11. 4 Open-market sale Sinha Vikas sold 939 shares at $0.72 ($676)
  12. 4 Open-market sale Chief Accounting Officer sold 304 shares at $0.72 ($219)
  13. 4 Open-market sale Chief Executive Officer sold 1,489 shares at $0.72 ($1,072)
  14. 4 Grant or award Director acquired 35,000 shares (grant or award)
  15. 4 Grant or award Director acquired 35,000 shares (grant or award)
  16. 4 Grant or award Director acquired 35,000 shares (grant or award)
  17. 4 Grant or award Director acquired 35,000 shares (grant or award)
  18. 4 Grant or award Director acquired 35,000 shares (grant or award)
  19. 4 Grant or award Director acquired 35,000 shares (grant or award)
  20. 4 Grant or award Director acquired 35,000 shares (grant or award)

Page 5 of 19 · 363 filings